SQZ® AAC Phase 1 Trial Observed Best Overall Response (BOR) of Stable Disease or Better in 60 Percent (3 of 5) of Treated Patients, Including One Patient with a Confirmed Complete ResponseSQZ® eAPC Phase 1/2 Trial Monotherapy Observed BOR of Stable Disease in 40 Percent (8 of 20) of Treated PatientsReduced Workforce.
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.